Jordanija - angleščina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - metformin hcl 1000 mg/1 tab , linagliptin 2.5 mg/1 tab - 1000 mg/1 tab , 2.5 mg/1 tab

Jordanija - angleščina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - metformin hcl 500 mg/1 tab , linagliptin 2.5 mg/1 tab - 500 mg/1 tab , 2.5 mg/1 tab

Jordanija - angleščina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - metformin hcl 850 mg/1 tab , linagliptin 2.5 mg/1 tab - 850 mg/1 tab , 2.5 mg/1 tab

Jordanija - angleščina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - metformin hcl 1000 mg/1 tab , linagliptin 2.5 mg/1 tab - 1000 mg/1 tab , 2.5 mg/1 tab

Kenija - angleščina - Pharmacy and Poisons Board

empagliflozin & linagliptin - tablet - empagliflozin 25 mg & linagliptin 5 mg - empagliflozin

Kenija - angleščina - Pharmacy and Poisons Board

empagliflozin + linagliptin - film-coated tablet - 10mg empagliflozin + 5mg linagliptin per tablet - metformin and empagliflozin

Malezija - angleščina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

boehringer ingelheim (malaysia) sdn. bhd. - linagliptin -

Evropska unija - angleščina - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin - diabetes mellitus, type 2 - drugs used in diabetes - trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Evropska unija - angleščina - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin, metformin - diabetes mellitus, type 2 - drugs used in diabetes, - treatment of adult patients with type-2 diabetes mellitus:jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.

Izrael - angleščina - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 25 mg - linagliptin and empagliflozin - jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.